Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Typhoid fever, a bacterial infection that causes high fever, headache and other symptoms, remains a serious health problem in the developing world. It kills almost a quarter of a million people annually, and infects about 21 million.

Stop typhoid message painted onto a hand © Shutterstock

The Bill and Melinda Gates Foundation has awarded the Typhoid Vaccine Acceleration Consortium (TyVAC), which includes the Oxford Vaccine Group, the University of Maryland School of Medicine (UM SOM) Center for Vaccine Development (CVD) and PATH, a nonprofit global health organization based in Seattle, a grant of more than $36.9 million (£29.8 million) to work on the introduction of, and access to, new and more effective typhoid vaccines. Their research will focus on conjugate vaccines, which can trigger a stronger immune response in vulnerable populations. 

Read more (Department of Paediatrics website)

 

Links

International Consortium Receives $36.9 Million Grant to Fight Typhoid (University of Maryland School of Medicine website)

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.